Clinical Trial Search

Primary: Effect on Cerebral Blood Flow in White Matter, Gray Matter, Deep White Matter, Deep Gray Matter, and Thalamus — 8.55; 5.12; 5.78; 2.06 Percentage of change in CBF

Primary: Time to Onset of 6-Month Confirmed Disability Progression (CDP) as Assessed by Expanded Disability Status Scale (EDSS) — 11.97; 12.04 months — p=0.0026

Primary: Expanded Disability Status Scale (EDSS) Improvement — 3.4; 3.3; 2.5; 3.7 units on a scale

Primary: Time to Confirmed Disease Progression (CDP) — NA; NA weeks — p=0.1442

Primary: Area Under the Curve (AUC) of the Combinatorial Weight-Adjusted Disability Score (CombiWISE) — 1.55; 0.80; 0.46; 0.89 units on a scale * year

Primary: Participant Retention Rate Over 12 Months — 352; 125 participants

Primary: Brain Atrophy by MRI — -0.4; -1.3 whole brain percent volume change

Primary: Percentage of Participants With 3-month Confirmed Disability Progression (CDP) Events as Measured by the Expanded Disability Status Scale (EDSS) — 26.3; 31.7 Percentage…

Primary: Summary of Raw Number of Cumulative Combined Unique Active Lesions in Patients With Relapsing Remitting Multiple Sclerosis by Visit and Treatment — 2.4; 3.2; 3.9; 5.4…

Primary: Total Number of Adverse Events During Evaluation of Long Term Safety and Tolerability of BAF312A in Extension Study. — 4; 7; 6; 6 events

Primary: Time to Onset of Clinical Disability Progression (CDP) Sustained for at Least 12 Weeks During the Double-Blind Treatment Period — NA; NA weeks

Primary: Expanded Disability Status Scale (EDSS) Plus — 17; 17 Participants — p=1.0

Primary: The Number of New or Recurrent Gd-enhancing Lesions That Appear on Brain T1-weighted MRI — 0.12 lesions

Primary: Core Treatment Period: Annualized Relapse Rate (ARR): Poisson Regression Estimate — 0.501; 0.389; 0.319 relapses per year — p=0.0001

Primary: Percentage Change in Whole Brain Volume — 0.288; 0.584 percentage of brain volumen change — p=0.003

Primary: FF-VEP Latency of the Affected Eye as Compared to the Baseline of the Fellow Eye at 2 Years (+ up to 12 Months) After the Last Study Visit Assessment (Week 32) in RENEW…

Primary: Annualized Relapse Rate (ARR) — 0.02 relapses per year

Primary: Change From Baseline in Patient-reported Treatment Satisfaction — 19.57; 5.83 score on a scale

Primary: Change in the Area Under the Curve (AUC) of the Combinatorial Weight-Adjusted Disability Score (CombiWISE) From Baseline to Treatment Phase — -0.13; -1.04 units on a…

Primary: Proportion of Research Cohort Subjects Referred Into a Clinical Trial or Offered Treatment With an Appropriate Second-line Therapy. — 178 Participants

Primary: Annualized Confirmed Relapse Rate — 0.202; 0.290 relapses per year — p=0.0003

Primary: Percentage of Participants With no Change or a Reduction From Baseline in the Number of Gadolinium Enhancing (GdE) Lesions at Month 12 Using Non-responder Imputation…

Primary: Number of Participants Developing a New MS Relapse and/or MRI Brain Lesion Over the Course of the Study Duration — 6; 16 Participants — p=0.521

Primary: Responder Rate of B-Cell Depletion at Week 4 — 87.5; 100.0; 87.5; 100.0 percentage of participants

Primary: Covariate-adjusted Mean Rate of Change in Brain Atrophy Over 96 Weeks as Measured by Brain Parenchymal Fraction (BPF). — -0.00168; -0.00392 ratio — p=0.04

Primary: Annualized Relapse Rate (ARR) From the Time of Cessation of Natalizumab Treatment. — 0 number of relapses in a year

Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs) — 17; 17; 24; 20 Participants

Primary: Mean Overall Response Score (ORS) — -0.74; -0.75; -0.64 score on a scale

Primary: Number of Combined Unique (CU) Active Magnetic Resonance Imaging (MRI) Lesions at Week 16 — 0.9; 3.0 lesions — p=<0.001

Primary: Annualized Relapse Rate (ARR) — 0.04; 0.03 relapses per year